Quantitative systems pharmacology: Landscape analysis of regulatory submissions to the US Food and Drug Administration

被引:36
|
作者
Bai, Jane P. F. [1 ]
Earp, Justin C. [1 ]
Florian, Jeffry [1 ]
Madabushi, Rajanikanth [1 ]
Strauss, David G. [1 ]
Wang, Yaning [1 ]
Zhu, Hao [1 ]
机构
[1] US FDA, Off Clin Pharmacol, Ctr Drug Evaluat & Res, Silver Spring, MD USA
来源
关键词
D O I
10.1002/psp4.12709
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Quantitative systems pharmacology (QSP) has been proposed as a scientific domain that can enable efficient and informative drug development. During the past several years, there has been a notable increase in the number of regulatory submissions that contain QSP, including Investigational New Drug Applications (INDs), New Drug Applications (NDAs), and Biologics License Applications (BLAs) to the US Food and Drug Administration. However, there has been no comprehensive characterization of the nature of these regulatory submissions regarding model details and intended applications. To address this gap, a landscape analysis of all the QSP submissions as of December 2020 was conducted. This report summarizes the (1) yearly trend of submissions, (2) proportion of submissions between INDs and NDAs/BLAs, (3) percentage distribution along the stages of drug development, (4) percentage distribution across various therapeutic areas, and (5) nature of QSP applications. In brief, QSP is increasingly applied to model and simulate both drug effectiveness and safety throughout the drug development process across disease areas.
引用
收藏
页码:1479 / 1484
页数:6
相关论文
共 50 条
  • [31] Physiologically Based Pharmacokinetic Modeling in Regulatory Science: An Update From the US Food and Drug Administration's Office of Clinical Pharmacology
    Grimstein, Manuela
    Yang, Yuching
    Zhang, Xinyuan
    Grillo, Joseph
    Huang, Shiew-Mei
    Zineh, Issam
    Wang, Yaning
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 108 (01) : 21 - 25
  • [32] US food and drug administration
    Goodman, Jesse
    ONCOLOGY-NEW YORK, 2006, 20 (08): : 946 - 946
  • [33] US Food and Drug Administration
    Blumenthal, G.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S37 - S37
  • [34] Pediatric dosing for locally acting drugs in submissions to the US Food and Drug Administration between 2002 and 2020
    Abulwerdi, Gelareh A.
    Ramamoorthy, Anuradha
    Bashaw, Edward
    Burckart, Gilbert J.
    Madabushi, Rajanikanth
    Fletcher, Elimika Pfuma
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 16 (10): : 2046 - 2057
  • [35] USAGE OF IN VITRO METABOLISM DATA FOR DRUG-DRUG INTERACTION (DDI) PREDICTION IN PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING SUBMISSIONS TO OFFICE OF CLINICAL PHARMACOLOGY, US FOOD AND DRUG ADMINISTRATION (FDA).
    Lee, J.
    Yang, Y.
    Zhang, X.
    Fan, J.
    Grimstein, M.
    Zhu, H.
    Wang, Y.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S104 - S104
  • [36] Correction to: A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021
    Gizem Kayki-Mutlu
    Zinnet Sevval Aksoyalp
    Leszek Wojnowski
    Martin C. Michel
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2023, 396 : 383 - 383
  • [37] Analysis of US Food and Drug Administration new drug and biologic approvals, regulatory pathways, and review times, 1980–2022
    Enrique Seoane-Vazquez
    Rosa Rodriguez-Monguio
    John H. Powers
    Scientific Reports, 14
  • [38] Clinical Evaluation of Pertussis Vaccines: US Food and Drug Administration Regulatory Considerations
    Farizo, Karen M.
    Burns, Drusilla L.
    Finn, Theresa M.
    Gruber, Marion F.
    Pratt, R. Douglas
    JOURNAL OF INFECTIOUS DISEASES, 2014, 209 : S28 - S31
  • [39] Regulatory review intervals for ophthalmic new drug applications at the US food and drug administration.
    Novack, GD
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P64 - P64
  • [40] REGULATORY POLICIES OF THE FOOD AND DRUG ADMINISTRATION
    MILLER, HI
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1989, 197 : 4 - CHAL